Concise Review: Human Pluripotent Stem Cells to Produce Cell-Based Cancer Immunotherapy.
Huang ZhuYi-Shin LaiYe LiRobert H BlumDan S KaufmanPublished in: Stem cells (Dayton, Ohio) (2018)
Human pluripotent stem cells (PSCs) provide a promising resource to produce immune cells for adoptive cellular immunotherapy to better treat and potentially cure otherwise lethal cancers. Cytotoxic T cells and natural killer (NK) cells can now be routinely produced from human PSCs. These PSC-derived lymphocytes have phenotype and function similar to primary lymphocytes isolated from peripheral blood. PSC-derived T and NK cells have advantages compared with primary immune cells, as they can be precisely engineered to introduce improved anti-tumor activity and produced in essentially unlimited numbers. Stem Cells 2018;36:134-145.